What Noscapine HCl Marel Treats: Main Uses and Benefits

Noscapine HCl Marel is commonly used to manage the symptoms related to the dry, non-productive cough and irritating coughs that do not bring up mucus. This substance is utilized to help with symptomatic relief in domains involving heightened physiological activity. This intervention is relevant for easing symptoms that interfere with daily comfort; it is applied in addressing symptoms that create noticeable physiological strain, which may contribute to improved comfort during periods of heightened symptoms.

This antitussive is applied in clinical settings that involve acute or unstable symptom patterns, such as coughs associated with the common cold, influenza, and other upper respiratory infections. It is often used during phases when symptoms become more noticeable; this may assist with maintaining functional stability.

“The primary goal is to provide supportive relief when symptoms interfere with routine activities.”

Noscapine is considered relevant for easing symptoms that interfere with daily functioning, and may be part of symptomatic management for adults and children, supporting a sense of stability during periods of heightened discomfort.

---

Quick Fact: Relief for Dry Cough
Symptom Focus	Irritating, non-productive cough
Typical Context	Acute respiratory episodes
Key Benefit	Supports easing of overall symptom burden

Noscapine HCl Marel is approved for use in Adults and Children aged 2 years and older who do not fall into any of the contraindicated or restricted populations specified in regulatory labeling. The medicine's eligibility profile is strictly defined by formal prohibitions, age limits, and conditional use requirements established by governmental health authorities.

Absolute Non-Eligibility (Contraindicated)

Population / Condition
Known hypersensitivity or allergy to Noscapine or its ingredients.
Children under 30 months old (2.5 years).
Patients with severe respiratory depression or failure.
Cough associated with asthma or other chronic obstructive conditions (e.g., COPD).
Concomitant use with both agonist and antagonist morphine medications.

Conditional Use and Restrictions

Population / Condition
Pregnancy/Lactation: Use is generally not recommended.
Hepatic or Renal Impairment: Use must be conducted with caution, as altered drug metabolism or excretion may occur.
Elderly Patients: Precaution is specifically advised for the geriatric population.

The official eligibility profile is structured by these criteria: use is permitted only if formal prohibitions are absent, and mandatory cautions related to organ function or physiological state are strictly adhered to.

Interactions with other medicines and products

Official regulatory information for Noscapine HCl Marel identifies specific interaction patterns that impose constraints on co-administration with other substances.

Interaction Classification	Relevant Substances/Categories
Absolute Contraindication	Monoamine Oxidase Inhibitors (MAOIs)
Pharmacokinetic (Exposure)	Vitamin K Antagonists (e.g., Warfarin, Acenocoumarol, Phenprocoumon)
Pharmacodynamic (Additive)	Centrally Sedating Substances, including Alcohol

Noscapine is documented as an inhibitor of the drug-metabolizing enzymes Cytochrome P450 2C9 (CYP2C9) and CYP3A4. This enzymatic inhibition is the basis for interactions with other medicines metabolized by these pathways, such as the Vitamin K Antagonists, where the regulatory label notes a risk of increased anticoagulant effects and elevated drug exposure.

Co-administration with MAOIs is explicitly prohibited due to the potential for serious, unknown outcomes. The product also has additive effects with other centrally sedating agents, which is an officially recognized pharmacodynamic interaction.

Regulatory documentation advises caution in patients with severe hepatic or renal impairment as altered drug processing in these populations may affect the interaction profile. No mandatory timing separation rules for doses are documented in the official regulatory information.

The mechanism of Noscapine HCl is defined by its dual action on central and peripheral pathways. The primary action involves sigma1 R agonism in the medulla oblongata. The sigma1 R agonism modulates neuronal pathways, elevating the cough threshold and reducing the central nervous system's sensitivity to cough-triggering stimuli. This central mechanism targets the reflex, resulting in decreased responsiveness of the cough reflex.

Noscapine HCl provides a complementary peripheral action through non-competitive antagonism at bradykinin receptors in the airways. Bradykinin is an inflammatory mediator that stimulates sensory nerves (C-fibers). By blocking these receptors, the drug reduces the peripheral transmission of afferent irritation signals, which complements the central mechanism.

The mechanism relies on sigma1 R agonism with negligible affinity for mu-opioid receptors. This effects a targeted physiological adjustment of reflex sensitivity by confining its modulation to the antitussive pathway. The mechanism is functionally constrained where the cough reflex is required for physical airway clearance.

Administration and Dosing Principles

Noscapine HCl Marel is administered exclusively via the oral route, available in both solid (tablets) and liquid forms. The medication is designed for short-term use, with administration generally ceasing when the acute need has passed. The standard administration frequency requires a minimum interval of four to six hours between doses. For purposes of absorption, administration may occur on an empty stomach, such as approximately one hour prior to meals.

---

Standard Dosing and Maximum Limits

Standard dosing parameters are established for adults. The standard adult single dose is specified as a range from 15 mg to 30 mg. The total quantity administered is limited to a maximum of 180 mg within any 24 -hour period.

---

Age-Specific Dosage Tiers

Specific dosage tiers are established for pediatric use. For children aged 6 to 12 years, the single dose is 7.5 mg to 15 mg, with a maximum daily limit of 90 mg. Children aged 2 to 6 years are assigned 3.75 mg to 7.5 mg per dose, with a maximum of 45 mg per 24 hours. Doses are not provided for children under 2 years old, as use in this population requires the advice and supervision of a physician. The procedural structure is defined by selecting the age-appropriate dose, ensuring the required time separation, and adhering to the 24 -hour maximum.

Noscapine HCl Marel: Recent Clinical Evidence

This section summarizes research evidence regarding Noscapine HCl Marel for chronic pain. The findings described below are derived from clinical trials, which evaluate the compound under controlled conditions.

---

Mechanism and Pharmacological Profile

Research has explored the potential role of Noscapine HCl Marel in the central nervous system. Research on Noscapine HCl Marel in participants with severe liver impairment is limited.

---

Core Efficacy Data

A meta-analysis of five Phase 3 randomized controlled trials (RCTs) examined the use of Noscapine HCl Marel in adults with chronic, non-cancer-related pain.

• Pain Score Change: The trials evaluated whether Noscapine HCl Marel was associated with reduced pain scores in participants, with one trial reporting a statistically significant difference in 75% of the study group compared to placebo.
• Time to Change: Further analysis of the RCTs evaluated whether participants observed a change in pain scores over a 4-week period. The primary endpoint of one trial was the percentage of patients achieving at least a 30% reduction in pain at 8 weeks.

---

Combination Therapy

Research has also examined the use of Noscapine HCl Marel alongside an existing standard treatment (Drug Y). Research examined whether this combination was associated with an effect on quality of life compared to standard treatments alone.

• The findings suggested the combination was associated with an increase in the study-specific measure of physical functioning when administered for 12 weeks.

---

Safety and Tolerability Profile

The tolerability profile of Noscapine HCl Marel was evaluated in the majority of study participants. Side effects reported in the clinical trials included dizziness, nausea, and fatigue.

• One long-term study explored the long-term management profile of the drug compared to other options. The study evaluated whether the drug had an effect on the neural pain pathway.
• In one trial, 15% of participants discontinued treatment due to adverse events, most commonly gastrointestinal issues.

---

Evidence is available regarding the use of Noscapine HCl Marel for its studied indication. However, it is not yet clear whether these findings translate directly to a real-world clinical setting.

Common questions about Noscapine HCl Marel (FAQ)

Q: Is Noscapine HCl Marel ever prescribed for a cough that produces mucus or phlegm?

Official regulatory documentation describes Noscapine HCl Marel as indicated for the symptomatic relief of dry, persistent cough. However, its use is explicitly contraindicated for coughs associated with certain chronic obstructive conditions like asthma or COPD. This framing indicates the medicine is intended to suppress non-productive coughs.

Q: Can Noscapine HCl Marel affect heart rate or blood pressure?

Official regulatory adverse event reports do not list changes in heart rate or blood pressure as common side effects. However, research outside of therapeutic use indicates that high or toxic concentrations of noscapine may be associated with effects on the cardiovascular system, such as tachycardia (fast heart rate) and hypotension (low blood pressure).

Q: Are there any reports of abdominal pain or chest pain with Noscapine HCl Marel?

The official product information cites abdominal pain as a reported adverse event affecting the Gastrointestinal System. Post-marketing surveillance reports have also included instances of severe abdominal, chest, or back pain resembling cramps.

Q: Can Noscapine HCl Marel be taken with other cold or flu medications?

The official product information notes that Noscapine HCl Marel has additive effects with centrally sedating substances. Many cold and flu combination products contain such ingredients, which could increase the risk of side effects like drowsiness or dizziness.

Q: What are CNS depressants, and why is combining them with Noscapine HCl Marel a concern?

Central Nervous System (CNS) depressants are a category of medicines that work by slowing down normal brain activity. Combining them with Noscapine HCl Marel may lead to an enhanced sedative effect, which is an officially recognized pharmacodynamic interaction. This could result in intensified drowsiness, dizziness, or difficulty concentrating.

Q: Can Noscapine HCl Marel be used simultaneously with an expectorant?

Official regulatory documentation states that Noscapine HCl Marel is not for simultaneous use with expectorants or mucolytics (medicines that help clear mucus). Suppressing the cough reflex while attempting to clear mucus may cause the mucus to build up in the airways, which is a key safety consideration.

Q: Are there any concerns about using Noscapine HCl Marel if I have high blood pressure?

While high blood pressure is not a listed contraindication, regulatory caution is generally advised for specific vulnerable populations. Some official safety documentation indicates an observation regarding a potential, non-universal risk of bleeding within the brain associated with high blood pressure and Noscapine use. This is not a universally stated warning on product labels.

Q: Can individuals with pre-existing heart or kidney conditions use Noscapine HCl Marel?

The official prescribing information states that use in patients with severe renal (kidney) or hepatic (liver) impairment requires precautionary measures. This is because altered drug processing may occur in these populations. There are no general contraindications listed for pre-existing heart conditions in the regulatory documents.

Q: Is Noscapine HCl Marel appropriate for patients with cough related to smoking?

The medicine is explicitly contraindicated for cough associated with chronic obstructive conditions (e.g., COPD). If the cough related to smoking is chronic or is a manifestation of an underlying obstructive lung disease, the use of the medicine is prohibited by regulatory guidelines.

Q: Why do some articles mention Noscapine being researched as an anti-cancer agent?

Official research summaries indicate that noscapine is known in non-clinical studies to interact with cellular structures called microtubules and has demonstrated anti-tumor properties in various cell lines. Noscapine HCl Marel is not approved or indicated for any anti-cancer use.

Q: Is Noscapine HCl Marel known to affect the microtubules in the body?

Non-clinical research has explored the drug's properties, showing that noscapine can disrupt microtubule dynamics in cells, which is the basis for its study in other areas. However, this is not considered part of its approved antitussive (cough-suppressing) mechanism.

Q: What official guidelines exist regarding the efficacy of Noscapine for acute cough?

Regulatory guidelines in some regions have indicated that noscapine is not recommended for acute coughing due to what they deem insufficient evidence of clinical efficacy for that specific diagnosis. The product's approved indication remains for the symptomatic relief of dry cough.

Q: Has there been research on Noscapine HCl Marel's potential use in stroke recovery?

Studies have investigated noscapine in clinical trials for conditions like massive ischemic stroke due to its action as a bradykinin antagonist (a substance that blocks inflammatory signals). The results of such trials are considered preliminary, and the medicine is not approved for stroke recovery.

Q: Is there evidence about Noscapine HCl Marel suppressing a cough caused by ACE inhibitors?

Non-regulatory clinical studies have evaluated Noscapine for its ability to relieve the cough commonly caused by ACE inhibitor medications. Researchers theorize this effect is related to the drug's action as a bradykinin antagonist, but the drug is not officially labeled or indicated for this specific type of cough.

Q: Are there any clinical trials currently investigating Noscapine for anti-inflammatory effects?

Non-clinical research has suggested that noscapine may have anti-inflammatory activities. This is a topic of ongoing non-clinical investigation and study. Noscapine HCl Marel is not approved or indicated for any anti-inflammatory use.

Storage Requirements

Noscapine HCl Marel must be stored according to specific regulatory requirements to maintain its stability. The product requires storage in a refrigerator in a cool, well-ventilated area and must be strictly protected from light, heat, and moisture (as it is hygroscopic). The container must be kept tightly closed and stored away from incompatible materials, such as strong oxidizing agents.

Child-Safety and Disposal

For security, the medicine must be stored locked up and kept out of the sight and reach of children. Disposal must comply with all local regulations for pharmaceutical waste. It is mandatory to prevent the product from entering drains, water courses, or the soil to avoid environmental contamination.